文献速递糖尿病

磺脲类治疗的ABCC8永久性新生儿糖尿病长期血糖与神经结局

Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes.
PubMed 文献 · Diabetes Care · 2020-11-12

该研究随访24例ABCC8-PNDM患者(21例获长期数据,中位随访10.0年),发现磺脲类治疗长期血糖控制优异,无严重低血糖,但神经发育特征常见且部分可改善,支持早期基因检测。

要点

  • 磺脲类治疗ABCC8-PNDM可长期维持优异血糖控制。
  • 神经发育特征常见,部分患者转药后改善。
  • 支持早期快速基因检测以指导治疗和神经评估。

核心结论

  • 磺脲类治疗ABCC8-PNDM可实现优异的长期血糖控制。
  • 神经发育特征常见,且可能随磺脲类治疗改善。

研究设计与样本

  • 研究纳入英国、意大利、法国和美国24例ABCC8-PNDM患者,均在2010年5月前从胰岛素转为磺脲类。
  • 采用非参数统计方法分析血糖控制、磺脲类剂量、低血糖等不良反应及神经特征。
  • 21例获得长期随访数据,中位随访10.0年(范围4.1-13.2年)。

主要发现

  • 磺脲类治疗前与转药后1年HbA1c分别为7.2%与5.7%(P=0.0004)。
  • 转药后1年与10年HbA1c分别为5.7%与6.5%(P=0.04,n=16)。
  • 转药后1年与10年格列本脲剂量分别为0.37与0.25 mg/kg/天(P=0.50),无严重低血糖。
  • 21例中13例报告神经特征,其中7例在转药后改善;最常见为学习困难(52%)、发育迟缓(48%)和注意缺陷多动障碍(38%)。

临床怎么用

  • 对ABCC8-PNDM患者应尽早进行快速基因检测以指导磺脲类治疗。
  • 治疗期间需监测神经发育特征并进行相应评估。

局限性

  • 样本量小(24例,长期数据仅21例)。
  • 为观察性随访,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: ABCC8 mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with ABCC8-PNDM require lower sulfonylurea doses and have milder neurological features than those with KCNJ11-PNDM. However, these studies were short-term and included combinations of ABCC8-PNDM and ABCC8-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated ABCC8-PNDM. RESEARCH DESIGN AND METHODS: We studied all 24 individuals with ABCC8-PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before May 2010. Data on glycemic control, sulfonylurea dose, adverse effects including hypoglycemia, and neurological features were analyzed using nonparametric statistical methods. RESULTS: Long-term data were obtained for 21 of 24 individuals (median follow-up 10.0 [range 4.1-13.2] years). Eighteen of 21 remained on sulfonylureas without insulin at the most recent follow-up. Glycemic control improved on sulfonylureas (presulfonylurea vs. 1-year posttransfer HbA1c 7.2% vs. 5.7%, P = 0.0004) and remained excellent long-term (1-year vs. 10-year HbA1c 5.7% vs. 6.5%, P = 0.04), n = 16. Relatively high doses were used (1-year vs. 10-year dose 0.37 vs. 0.25 mg/kg/day glyburide, P = 0.50) without any severe hypoglycemia. Neurological features were reported in 13 of 21 individuals; these improved following sulfonylurea transfer in 7 of 13. The most common features were learning difficulties (52%), developmental delay (48%), and attention deficit hyperactivity disorder (38%). CONCLUSIONS: Sulfonylurea treatment of ABCC8-PNDM results in excellent long-term glycemic control. Overt neurological features frequently occur and may improve with sulfonylureas, supporting early, rapid genetic testing to guide appropriate treatment and neurodevelopmental assessment.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bowman P, Mathews F, Barbetti F, et al. Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes. Diabetes Care. 2020. PMID: 33184150. doi:10.2337/dc20-1520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。